Mechanistically compelling, preclinically validated, but clinically unproven
Most preclinical BPC-157 research has used injectable delivery methods in animal subjects
Complete reconstitution chart: 30mg tirzepatide vial The 30mg vial is the workhorse of longer research protocols
No irritation
In 1981, for example, a paper published in the International Journal of Clinical Pharmacology, Therapy, and Toxicology described a trial with six volunteers who experienced immediate sleep pressure after intravenous DSIP infusion, as well as increased sleep time, decreased sleep onset, and better sleep efficiency without any sedative effects.13 Three years later, two other human trials across ten test subjects with insomnia found that DSIP administration yielded statistically significant improvements in several key sleep measures fewer sleep arousals, greater sleep efficiency, and increased REM, spindle, and slow-wave sleep.14 The above studies had shortcomings, namely their very small sample sizes, but the sleep-improving effects in cases of insomnia point to DSIPs potential to live up to its name
The cursory pharmacokinetic characterization of dihexa included in this study indicated that it was stable in serum, had a long circulating half-life, and penetrated the BBB
